Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

Eligibility Criteria

• * Males and females between 40 and 75 years of age capable and willing to provide informed consent
• * Participant has high CAD PRS as defined on a clinical test
• * Participant with subclinical atherosclerosis defined as plaque visible on CCTA and causing \<70% luminal stenosis
• * Participant with a history of cardiovascular disease, defined by a diagnosis of coronary artery disease, peripheral artery disease, or cerebrovascular disease
• * Participant with a history of Liver disease (cirrhosis, active hepatitis, or severe hepatic disease) or any of the following recent lab results and determined to be non-transient: alanine aminotransferase greater than 3 times the upper limit of normal or total bilirubin greater than 2 times the upper limit of normal (unless due to Gilbert syndrome)
• * Participant with estimated glomerular filtration rate \<60 mL/min/1.73 m2 or creatinine greater than 2 times the upper limit of normal
• * Patient with history of an allergic reaction or significant sensitivity to iodinated contrast, colchicine, or statins
• * Patient currently taking LDL cholesterol lowering or anti- inflammatory medications including colchicine
• * Participants requiring regular drugs known to be potent CY2P inhibitors (eg. ketoconazole, clarithromycin)
• * Female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study
• * Participant with BMI ≥ 40 kg/m2
• * Participant unable to provide informed consent
• * Participant unable to hold breath for 10 seconds